Imiquimod for Cervical and Vaginal Intraepithelial Neoplasia

    July 2023 in “ Obstetrics & Gynecology
    Yoshihide Inayama, Shiro Takamatsu, Junzo Hamanishi, Kayoko Mizuno, Noboru Horinouchi, Koji Yamanoi, Mana Taki, Ryusuke Murakami, Ken Yamaguchi, Kenzo Kosaka, Orestis Efthimiou, Koji Kawakami, Toshi A Furukawa, Masaki Mandai
    Image of study
    TLDR Imiquimod may be a better non-surgical treatment for cervical pre-cancer, but its effectiveness for vaginal pre-cancer is unclear, and it has some side effects.
    The systematic review and meta-analysis evaluated the effectiveness and side effects of imiquimod, a topical medication, for treating Cervical Intraepithelial Neoplasia (CIN) and Vaginal Intraepithelial Neoplasia (VAIN). The study found that imiquimod is potentially a superior alternative to surgery for CIN, with a pooled odds ratio (OR) for histologic regression of 4.27 (95% CI 2.11–8.66). However, data on its effectiveness for VAIN was inconclusive. Adverse events were common, but less than 10% of patients discontinued treatment, indicating that imiquimod is generally well-tolerated. Three cases of temporary hair loss were reported, but it was reversible in all cases. The study recommends further research to optimize imiquimod administration and manage adverse events.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 441 results